Initial assessment of the COVID-19 vaccination's impact on case numbers, hospitalisations and deaths in people aged 80 years and older, 15 EU/EEA countries, December 2020 to May 2021.

COVID-19 health impact assessment mass vaccination vaccination uptake

Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
12 2021
Historique:
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 15 12 2021
Statut: ppublish

Résumé

Prioritisation of elderly people in COVID-19 vaccination campaigns aimed at reducing severe outcomes in this group. Using EU/EEA surveillance and vaccination uptake, we estimated the risk ratio of case, hospitalisation and death notifications in people 80 years and older compared with 25-59-year-olds. Highest impact was observed for full vaccination uptake 80% or higher with reductions in notification rates of cases up to 65% (IRR: 0.35; 95% CI: 0.13-0.99), hospitalisations up to 78% (IRR: 0.22; 95% CI: 0.13-0.37) and deaths up to 84% (IRR: 0.16; 95% CI: 0.13-0.20).

Identifiants

pubmed: 34857068
doi: 10.2807/1560-7917.ES.2021.26.48.2101030
pmc: PMC8641072
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
BMC Infect Dis. 2015 Oct 17;15:429
pubmed: 26474974
Euro Surveill. 2020 Mar;25(9):
pubmed: 32156327
Euro Surveill. 2021 Jul;26(28):
pubmed: 34269175
Euro Surveill. 2021 Oct;26(41):
pubmed: 34651577
Nat Med. 2021 Dec;27(12):2108-2110
pubmed: 34728830

Auteurs

Nathalie Nicolay (N)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Francesco Innocenti (F)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.
Epidemiology Unit, Regional Health Agency of Tuscany, Florence, Italy.

Julien Beauté (J)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Veronika Učakar (V)

National institute of Public Health, Ljubljana, Slovenia.

Marta Grgič Vitek (M)

National institute of Public Health, Ljubljana, Slovenia.

Eero Poukka (E)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Tuula Hannila-Handelberg (T)

Finnish Institute for Health and Welfare, Helsinki, Finland.

Charmaine Gauci (C)

Health Promotion and Disease Prevention Directorate, Msida, Malta.

Tanya Melillo (T)

Health Promotion and Disease Prevention Directorate, Msida, Malta.

Theano Georgakopoulou (T)

Department of Epidemiological Surveillance and Intervention of the National Public Health Organization (NPHO), Athens, Greece.

Jiri Jarkovsky (J)

Data analysis department, Institute of Health Information and Statistics of the Czech Republic, Prague, Czechia.

Pavel Slezak (P)

Department of Infectious Diseases Epidemiology, National Institute of Public Health, Prague, Czechia.

Concepción Delgado-Sanz (C)

National Epidemiology Centre, CIBERESP, Institute of Health Carlos III, Madrid, Spain.

Carmen Olmedo-Lucerón (C)

Area Immunisation Programme. Ministry of Health, Madrid, Spain.

Heleene Suija (H)

Department of Communicable Diseases, Health Board, Tallin, Estonia.

Rasa Liausediene (R)

National Public Health Centre, Vilnius, Lithuania.

Piaras O'Lorcain (P)

Health Protection Surveillance Centre, Dublin, Ireland.

Niamh Murphy (N)

Health Protection Surveillance Centre, Dublin, Ireland.

André Peralta-Santos (A)

Directorate of Information and Analysis, Directorate-General of Health, Lisbon, Portugal.

Pedro Casaca (P)

Directorate of Information and Analysis, Directorate-General of Health, Lisbon, Portugal.

Ioanna Gregoriou (I)

Ministry of Health, Nicosia, Cyprus.

Nick Bundle (N)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Gianfranco Spiteri (G)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Giovanni Ravasi (G)

European Centre for Disease Prevention and Control (ECDC), Solna, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH